Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;88(9):748-755.
doi: 10.1007/s00104-017-0469-1.

[R1 resection of esophageal carcinoma]

[Article in German]
Affiliations
Review

[R1 resection of esophageal carcinoma]

[Article in German]
I Gockel et al. Chirurg. 2017 Sep.

Abstract

The microscopic identification of residual tumor tissue in the oral or aboral resection margins (R1 resection) of esophageal specimens following oncologic esophageal resection, increases the risk of tumor recurrence and disease-related morbidity. Esophageal resection with its associated risks is only meaningful, if an R0 situation can be safely achieved. The relevance of microscopic involvement of the circumferential resection margin (CRM) in esophageal carcinoma in its different definitions by the British and the American Societies of Pathology has up to now never been investigated in a prospective study. According to the German S3 guideline, radiochemotherapy should be performed in a postoperatively proven R1 situation, which cannot be converted by a curative extended re-resection into an R0 situation or in unfavorable conditions for an extended re-resection, independent of neoadjuvant therapy. In the case of an R1 situation in the region of the CRM, an extended re-resection is not simply possible on account of the anatomical conditions with corresponding limitations by the aorta and the spinal column, in contrast to extensions of the re-resection orally or aborally.

Keywords: Esophagectomy; Local recurrence; Prognosis; Radiochemotherapy; Re-resection.

PubMed Disclaimer

References

    1. Eur J Cancer. 1998 Mar;34(4):503-9 - PubMed
    1. Br J Surg. 1976 Apr;63(4):259-62 - PubMed
    1. J Surg Oncol. 2016 Oct;114(5):642-648 - PubMed
    1. Eur J Surg Oncol. 2000 Dec;26(8):810-4 - PubMed
    1. Ann Surg. 2016 Apr;263(4):712-8 - PubMed

LinkOut - more resources